/DERM
DERM Stock - Journey Medical Corporation
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$7.87-0.63%
$0.05 (-0.63%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.63
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.88
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+49.3%upside
Target: $11.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DERM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.79 – $7.95
TARGET (TP)$11.75
STOP LOSS$7.24
RISK/REWARD1:6.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.81
52W High$9.40
52W Low$3.54
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $56.13M | $79.18M | $73.67M | $63.13M | $44.53M |
| Gross Profit | $35.26M | $52.52M | $42.89M | $31.05M | $29.94M |
| Gross Margin | 62.8% | 66.3% | 58.2% | 49.2% | 67.2% |
| Operating Income | $-13,677,000 | $-2,073,000 | $-27,517,000 | $-34,881,000 | $7.85M |
| Net Income | $-14,672,000 | $-3,853,000 | $-29,628,000 | $-43,994,000 | $5.28M |
| Net Margin | -26.1% | -4.9% | -40.2% | -69.7% | 11.9% |
| EPS | $-0.72 | $-0.21 | $-1.69 | $-2.54 | $0.32 |
Company Overview
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 42.9% Upside
Now
$9
Low
$11
Average
$13
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 25th 2025 | H.C. Wainwright | Initiation | Buy | $13 |
| July 30th 2025 | B. Riley Securities | Resumed | Buy | $12 |
| August 22nd 2024 | Rodman & Renshaw | Initiation | Buy | $9 |
| June 28th 2024 | ROTH MKM | Resumed | Buy | $11 |
Earnings History & Surprises
DERMBeat Rate
29%
Last 17 quarters
Avg Surprise
-11.4%
EPS vs Estimate
Beats / Misses
5/12
Last 12 quarters
Latest EPS
$-0.09
Q4 2025
EPS Surprise History
Q1 24
-50.0%
$-0.12vs$-0.08
Q2 24
-103.8%
$-0.53vs$-0.26
Q3 24
-13.3%
$-0.17vs$-0.15
Q4 24
+29.4%
$-0.12vs$-0.17
Q1 25
+136.4%
$0.08vs$-0.22
Q2 25
+25.0%
$-0.18vs$-0.24
Q3 25
-128.6%
$-0.16vs$-0.07
Q4 25
-12.5%
$-0.09vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.06 | — | — | — |
Q1 2026 | Mar 19, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.07 | $-0.16 | -128.6% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.24 | $-0.18 | +25.0% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.22 | $0.08 | +136.4% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.15 | $-0.17 | -13.3% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.26 | $-0.53 | -103.8% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.08 | $-0.12 | -50.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.15 | $0.80 | +633.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.34 | $-0.46 | -35.3% | ✗ MISS |
Q2 2023 | May 22, 2023 | $-0.44 | $-0.57 | -29.5% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.37 | $-0.60 | -62.2% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.34 | $-0.57 | -67.6% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.25 | $-0.43 | -72.0% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.18 | $-0.08 | +55.6% | ✓ BEAT |
Q1 2022 | Mar 23, 2022 | $-0.29 | $-1.64 | -465.5% | ✗ MISS |
Q4 2021 | Dec 10, 2021 | $-0.87 | $-1.16 | -33.6% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | — | $-1.30 | — | — |
Latest News
Journey Medical Highlights Publication Of Emrosi Trial Results In Journal of Drugs in Dermatology
📈 PositiveBenzinga•Dec 10, 2025, 01:34 PM
Journey Medical Q3 EPS $(0.09) Misses $(0.04) Estimate, Sales $17.631M Miss $18.854M Estimate
📉 NegativeBenzinga•Nov 12, 2025, 09:02 PM
Journey Medical Corporation Releases Pooled Phase 3 Data From Its MVOR-1 And MVOR-2 Trials Evaluating DFD-29 Demonstrating Emrosi's Statistical Superiority Over Oracea And Placebo In Achieving Investigator's Global Assessment Treatment Success And Reducing Inflammatory Lesion Counts
📈 PositiveBenzinga•Oct 24, 2025, 12:33 PM
Journey Medical May Sell 3,750,000 Shares Of Common Stock
➖ NeutralBenzinga•Aug 28, 2025, 09:34 PM
HC Wainwright & Co. Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $13
📈 PositiveBenzinga•Aug 25, 2025, 11:35 AM
Frequently Asked Questions about DERM
What is DERM's current stock price?
Journey Medical Corporation (DERM) is currently trading at $7.87 per share. The stock has moved -0.63% today.
What is the analyst price target for DERM?
The average analyst price target for DERM is $11.75, based on 1 analyst.
What sector is Journey Medical Corporation in?
Journey Medical Corporation operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is DERM's market cap?
Journey Medical Corporation has a market capitalization of $0.18 billion, making it a small-cap company.
Does DERM pay dividends?
No, Journey Medical Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorFENC
Fennec Pharmaceuticals Inc.
$7.66
Mkt Cap: $0.2B
HSDT
Solana Company
$2.98
Mkt Cap: $0.1B
IVA
Inventiva S.A.
$4.21
Mkt Cap: $0.2B
MDWD
MediWound Ltd.
$18.77
Mkt Cap: $0.2B
NYXH
Nyxoah S.A.
$4.85
Mkt Cap: $0.2B
OBIO
Orchestra BioMed Holdings, Inc.
$4.35
Mkt Cap: $0.2B
OGI
Organigram Global Inc.
$2.01
Mkt Cap: $0.3B
OSUR
OraSure Technologies, Inc.
$2.39
Mkt Cap: $0.2B
RNAC
Cartesian Therapeutics, Inc.
$7.22
Mkt Cap: $0.2B
SXTC
China SXT Pharmaceuticals, Inc.
$1.61
Mkt Cap: $0.2B
Explore stocks similar to DERM for comparison